文献速递肿瘤 PET/CT放射性药物与辐射防护

靶向人CD8β的纳米抗体放射性示踪剂对人CD8+ T细胞动态进行特异性成像

Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-09-02

本研究开发了靶向人CD8β的纳米抗体免疫示踪剂,用锝-99m、镓-68和铜-64标记后,在CD8转基因小鼠、荷瘤小鼠和非人灵长类中通过SPECT/CT或PET/CT实现CD8+ T细胞的无创显像,显示出高亲和力、特异性结合且无不良免疫激活,相比既往人CD8靶向示踪剂具有更高特异性和/或更快体内药代动力学,可在早期时间点追踪CD8+ T细胞动态。

要点

  • 靶向人CD8β的纳米抗体免疫示踪剂对人CD8具有高亲和力和特异性结合,且不引起不良免疫激活。
  • 该示踪剂经锝-99m、镓-68和铜-64标记后,可在小鼠和非人灵长类中通过SPECT/CT或PET/CT高灵敏度无创显像CD8+ T细胞。
  • 相比既往人CD8靶向免疫示踪剂,该示踪剂对CD8+ T细胞特异性更高和/或体内药代动力学更快,可在早期时间点追踪人CD8+ T细胞动态。

核心结论

  • 本研究开发了一种更特异的人CD8+ T细胞靶向免疫示踪剂,可通过无创成像人CD8+ T细胞动态来随访免疫治疗反应。

研究设计与样本

  • 通过美洲驼免疫和后续生物淘选生成靶向人CD8β的纳米抗体,并对先导抗人CD8β纳米抗体进行结合、特异性、稳定性和毒性表征。
  • 先导纳米抗体用锝-99m、镓-68和铜-64标记,在人T细胞淋巴瘤、人CD8转基因小鼠和非人灵长类中通过SPECT/CT或PET/CT进行无创显像。
  • 在MC38荷瘤小鼠中重复成像CD8+ T细胞以可视化CD8+ T细胞动态。

主要发现

  • 纳米抗体免疫示踪剂对人CD8显示出高亲和力和特异性结合,且无不良免疫激活。
  • 在naïve和荷瘤小鼠以及naïve非人灵长类中,通过SPECT和PET成像以高灵敏度无创可视化CD8+ T细胞。
  • 相比既往人CD8靶向免疫示踪剂,该纳米抗体免疫示踪剂对CD8+ T细胞显示出更高特异性和/或更快体内药代动力学,允许在早期时间点追踪人CD8+ T细胞动态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: While immunotherapy has revolutionized the oncology field, variations in therapy responsiveness limit the broad applicability of these therapies. Diagnostic imaging of immune cell, and specifically CD8+ T cell, dynamics could allow early patient stratification and result in improved therapy efficacy and safety. In this study, we report the development of a nanobody-based immunotracer for non-invasive SPECT and PET imaging of human CD8+ T-cell dynamics. METHODS: Nanobodies targeting human CD8β were generated by llama immunizations and subsequent biopanning. The lead anti-human CD8β nanobody was characterized on binding, specificity, stability and toxicity. The lead nanobody was labeled with technetium-99m, gallium-68 and copper-64 for non-invasive imaging of human T-cell lymphomas and CD8+ T cells in human CD8 transgenic mice and non-human primates by SPECT/CT or PET/CT. Repeated imaging of CD8+ T cells in MC38 tumor-bearing mice allowed visualization of CD8+ T-cell dynamics. RESULTS: The nanobody-based immunotracer showed high affinity and specific binding to human CD8 without unwanted immune activation. CD8+ T cells were non-invasively visualized by SPECT and PET imaging in naïve and tumor-bearing mice and in naïve non-human primates with high sensitivity. The nanobody-based immunotracer showed enhanced specificity for CD8+ T cells and/or faster in vivo pharmacokinetics compared to previous human CD8-targeting immunotracers, allowing us to follow human CD8+ T-cell dynamics already at early timepoints. CONCLUSION: This study describes the development of a more specific human CD8+ T-cell-targeting immunotracer, allowing follow-up of immunotherapy responses by non-invasive imaging of human CD8+ T-cell dynamics.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. De Groof TWM, Lauwers Y, De Pauw T, et al. Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β. Eur J Nucl Med Mol Imaging. 2024. PMID: 39218831. doi:10.1007/s00259-024-06896-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。